Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
NVIDIA's continued investment in Recursion Pharmaceuticals strengthens the view that Recursion is a favored investment within ...
Could this Nvidia-backed growth stock be a millionaire-maker at $10?
This little-known artificial intelligence growth stock is backed by chipmaker Nvidia and recently jumped nearly 24% in a ...
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week
We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a ...
SoftBank adds to shares in VTEX, YMM, cuts NMRA and exits DASH, among other moves
The Japanese investment holding company SoftBank Group ( OTCPK:SFTBY) purchased two new stakes: 20.45M shares in Pacific Biosciences of California ( PACB ), and 14.66M shares in Recursion ...
Biotechs on the Brink: 2 Stocks With Huge Potential
Detailed price information for Briacell Therapeutics Corp (BCTX-Q) from The Globe and Mail including charting and trades.
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Hosted on MSN10d
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.9% higher at $8.34. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Recursion Pharmaceuticals files automatic mixed securities shelf
EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...